Nexalin Technology announced it has closed the acquisition of PONM, an AI-integrated digital health platform that powers the company’s HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic. Nexalin said the deal gives it ownership and an exclusive license to software features that support AI-enabled remote patient monitoring, treatment-compliance data capture, electronic health record functionality, virtual-clinic management, and real-time analytics.
The platform is already deployed at UC San Diego, where it supports headset usage tracking, remote prescribing, physician oversight, and clinical research workflows. Nexalin positions the integrated “device-plus-software” approach as a key part of its planned regulatory and commercialization pathway, including readiness for a 160-participant FDA pivotal trial of HALO Clarity for moderate-to-severe insomnia, with enrollment expected to begin in Q2 2026.
For behavioral health AI audiences, the news is a clear example of where the market is heading: combining at-home, physician-supervised interventions with AI-supported monitoring, adherence tracking, and virtual-care infrastructure to operationalize safety, oversight, and scalable care delivery.